{"id":3220,"date":"2025-08-06T16:20:06","date_gmt":"2025-08-06T07:20:06","guid":{"rendered":"https:\/\/atlas.ncc.go.jp\/?page_id=3220"},"modified":"2025-08-06T16:20:06","modified_gmt":"2025-08-06T07:20:06","slug":"CHOICE","status":"publish","type":"page","link":"https:\/\/atlas.ncc.go.jp\/en\/CHOICE\/","title":{"rendered":"CHOICE Study"},"content":{"rendered":"

Overview<\/h2>\r\n

The CHOICE Study is a prospective clinical study to identify the clinical characteristics of patients with advanced cholangiocarcinoma who harbor the fibroblast growth factor receptor (FGFR) 2 rearrangement.
\r\nThis study will be focusing on patients from Asian countries, to have a better understanding of the distribution and frequency of patients with FGFR2 fusion gene-positive cholangiocarcinoma in Asia, which has not been clarified yet. Another focus of this study is the use of two gene testing methods; FISH and NGS, to identify the FGFR2 fusion gene in this specific population.<\/p>\r\n

Progress<\/h4>\r\n

The patient registration period for this study has been ended. Data analysis is currently underway. (As of May 2024)<\/p>\r\n

Background<\/h2>\r\n

Globally, cholangiocarcinoma is classified as a rare cancer, but its incidence rates exhibit geographical variation, with much higher incidence in Asia compared to the western countries. It is a highly aggressive cancer with poor prognosis due to limited treatment options. However, several new target molecules have recently been discovered, giving us a clue for improving therapeutic approaches for this cancer. One molecule that has gained attention is the FGFR2 fusion gene, with several molecular targeted agents under investigation worldwide. Despite the high frequently of cholangiocarcinoma reported in the Asia-Pacific region, clinical and biomarker data are lacking from these areas, which results in the drug development to be centered outside of Asia-Pacific, such as Europe, the United States, and Japan. Therefore, more studies are needed to elucidate the molecular background of cholangiocarcinoma patients from the Asian countries.
\r\nThis study is conducted as an Asian multicenter prospective study to comprehensively investigate FGFR2 fusion genes and other genomic alterations in patients with metastatic and\/or recurrent cholangiocarcinoma. The study name comes from: \u201cMolecular detection and clinicopathological characteristics of advanced\/recurrent CHOlangiocarcinoma harboring FGFR2 rearrangements In Asian CountriEs: CHOICE study,\u201d and is as part of the NCCH\u2019s project for promoting rare cancer research and development and genomic medicine in Asia, \u201cMarker Assisted Selective ThErapy in Rare cancers: Knowledge database Establishing registry, Asia; MASTER KEY Asia\u201d (Note 3).
\r\nMASTER KEY Asia, a global study in Asia, was expanded from the \u201cMASTER KEY Project\u201d (Note 4) launched in 2017 in Japan for driving research and development on rare cancers and for promoting genomic medicine, and has become a successful collaboration between industry and academia. MASTER KEY Asia has two major purposes: (1) to comprehensively collect molecular information on patients with rare cancers along with the treatment and prognosis data to establish a large-scale database serving as basic study data and (2) to conduct multiple investigator- or industry-initiated trials in patients with rare cancers or a specific biomarker irrespective of cancer type.
\r\nCHOICE study will collect data on patients with cholangiocarcinoma from Asia, adding on to the MASTER KEY Project (Japan), to build an all-Asia database for cholangiocarcinoma patients and contributing to the elucidation of its pathogenesis. We believe that the study will give hope for improving treatment of patients suffering from this cancer not only for the Asian region but for patients worldwide.<\/p>\r\n

ClinicalTrials.gov registration number<\/h2>\r\n

NCT05217407<\/a><\/span><\/p>\r\n

Origin of the logomark & mascot-character<\/h2>\r\n

The CHOICE-study\u2019s logo was designed based on the MASTER KEY Asia\u2019s logo, as both studies share the same platform while being conducted under the ATLAS project.
\r\nThe shape of the key is designed with an arrow representing \u201cchoice\u201d at the right end and a blank space surrounding it which represents the letter “C”.
\r\nThe coloring is based on “kelly green,” the symbolic color of biliary tract cancer.<\/p>\r\n

\"CHOICE\u8a66\u9a13\u30ed\u30b4\u30de\u30fc\u30af\"<\/div>\r\n

“Billy-kun” is a cheerful mascot character of the CHOICE study. He is an active boy born on Master Key Island, along with “Master-kun” and “Key-chan”, the lovable mascot characters of the MASTER KEY Asia study.
\r\nHe continues his various adventures\u3000day in day out, with a compass in his hand, seeking the truth in the treatment of cholangiocarcinoma.<\/p>\r\n

\"CHOICE\u8a66\u9a13\u30de\u30b9\u30b3\u30c3\u30c8\"<\/div>","protected":false},"excerpt":{"rendered":"Overview The CHOICE Study is a prospective clinical study to identify the clinical characteristics of patients with advanced cholangiocarcinoma who harbor the fibroblast growth factor receptor (FGFR) 2 rearrangement. This study will be focusing on patients from Asian countries, to have a better understanding of the distribution and frequency of patients with FGFR2 fusion gene-positive […]","protected":false},"author":23,"featured_media":0,"parent":0,"menu_order":80,"comment_status":"closed","ping_status":"closed","template":"page-CHOICE.php","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"https:\/\/atlas.ncc.go.jp\/atlasprj_cms\/?page_id=1897","footnotes":""},"class_list":["post-3220","page","type-page","status-publish","hentry","en-US"],"acf":{"project_logo":"https:\/\/atlas.ncc.go.jp\/atlasprj_cms\/wp-content\/themes\/atlas_new\/common\/img\/index\/main_v8.jpg"},"_links":{"self":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/pages\/3220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/comments?post=3220"}],"version-history":[{"count":3,"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/pages\/3220\/revisions"}],"predecessor-version":[{"id":3241,"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/pages\/3220\/revisions\/3241"}],"wp:attachment":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/media?parent=3220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}